Compared to no evidence from the target population, the more frequent observation of improvements in precancerous gastric pathology observed in participants whose Hp density reduced during follow-up relative to those whose Hp density did not constitutes compelling evidence that treatment to eliminate Hp infection has the potential to reduce stomach cancer risk in participating communities. This evidence concerns the gene HP and gastric neoplasm.